P/E ratio for Gilead Sciences (GILD)

P/E ratio history for Gilead Sciences from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Amgen AMGN	25.1	33.89%	🇺🇸 USA
Vertex Pharmaceuticals VRTX	32.9	75.43%	🇺🇸 USA
AbbVie ABBV	164	771.72%	🇺🇸 USA
Illumina ILMN	31.5	67.80%	🇺🇸 USA
Biogen BIIB	17.1	-8.64%	🇺🇸 USA
Pfizer PFE	14.8	-21.31%	🇺🇸 USA
Johnson & Johnson JNJ	19.6	4.63%	🇺🇸 USA
Eli Lilly LLY	52.5	179.98%	🇺🇸 USA
Merck MRK	14.7	-21.86%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.